Lakefront Biotherapeutics NV (LKFT)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Lakefront Biotherapeutics N.V.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 34.50 | 35.15 | 34.45 | 34.79 | 292,602 |
| Nov 13, 2026 | 33.72 | 34.14 | 33.22 | 33.98 | 287,838 |
| Nov 12, 2026 | 34.20 | 35.54 | 33.75 | 33.93 | 535,522 |
| Nov 11, 2026 | 32.99 | 33.42 | 32.95 | 33.34 | 195,183 |
| Nov 10, 2026 | 32.95 | 33.48 | 32.80 | 33.41 | 228,631 |
| Nov 9, 2026 | 33.80 | 34.15 | 33.33 | 33.52 | 325,971 |
| Nov 6, 2026 | 32.30 | 33.60 | 32.27 | 33.45 | 374,143 |
| Nov 5, 2026 | 34.09 | 34.49 | 33.51 | 33.56 | 342,321 |
| Nov 4, 2026 | 33.09 | 34.13 | 32.85 | 34.09 | 447,220 |
| Nov 3, 2026 | 32.25 | 32.45 | 31.98 | 32.15 | 129,706 |
| Nov 2, 2026 | 32.44 | 32.50 | 31.90 | 32.02 | 259,070 |
| Oct 30, 2026 | 32.42 | 32.76 | 32.06 | 32.28 | 164,056 |
| Oct 29, 2026 | 32.24 | 32.60 | 32.01 | 32.33 | 245,964 |
| Oct 28, 2026 | 31.65 | 32.41 | 31.51 | 32.08 | 268,990 |
| Oct 27, 2026 | 31.57 | 31.82 | 31.27 | 31.82 | 170,822 |
| Oct 26, 2026 | 31.81 | 32.00 | 31.62 | 31.68 | 191,351 |
| Oct 23, 2026 | 31.36 | 31.79 | 31.19 | 31.65 | 294,937 |
| Oct 22, 2026 | 30.62 | 31.53 | 30.55 | 31.40 | 307,947 |
| Oct 21, 2026 | 30.75 | 30.86 | 30.36 | 30.58 | 134,158 |
| Oct 20, 2026 | 29.97 | 30.86 | 29.97 | 30.75 | 293,687 |
| Name | Shares | % | Source |
|---|---|---|---|
Gilead Sciences, Inc. · also on 13F· may incl. warrants· filed Jan 2025 | 21.0M | 31.8% | 13D |
GILEAD SCIENCES, INC. | 16.7M | 25.4% | 13F |
EcoR1 Capital, LLC · also on 13F· may incl. warrants· filed Jul 2025 | 8.7M | 13.2% | 13D |
TANG CAPITAL MANAGEMENT, LLC · also on 13F· filed Oct 2025 | 5.6Mall common | 8.4% | 13G |
TANG CAPITAL MANAGEMENT LLC | 3.8M | 5.7% | 13F |
Madison Avenue Partners, LP | 3.5M | 5.3% | 13F |
FMR LLC · also on 13F· may incl. warrants· filed Nov 2024 | 2.6M | 3.9% | 13G |
Prosight Management, LP | 2.0M | 3.0% | 13F |
EcoR1 Capital, LLC | 1.7M | 2.5% | 13F |
UBS Group AG | 647.5K | 1.0% | 13F |
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics.
Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis.
The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
based on 65.90M shares outstanding
30d Avg
268.08K
60d Avg
290.02K
90d Avg
284.13K
Lakefront Biotherapeutics NV (NASDAQ: LKFT) traded at $34.79 on Nov 16, 2026, up 2.38% from the previous close of $33.98. 52-week range: $26.42 to $37.78. The company is in the Healthcare sector (Biotechnology).